Balchem Corporation (NASDAQ:BCPC) Q3 2020 Earnings Conference Call October 28, 2020 11:00 AM ET Company Participants Martin Bengtsson - Chief Financial Officer Ted Harris - Chairman, Chief Executive Officer & President Conference Call Participants Bob Labick - CJS Securities Ram Selvaraju - H.C. Wainwright Mark Connelly - Stephens Mitra Ramgopal - Sidoti & Company Operator Greetings. Welcome to the Balchem Corporation Financial Results Conference Call. At this time, all participants are in a listen-only mod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 1-136 ...

Balchem Corporation (NASDAQ:BCPC) Q2 2020 Earnings Conference Call July 31, 2020 11:00 AM ET Company Participants Martin Bengtsson - Chief Financial Officer Ted Harris - Chairman, Chief Executive Officer & President Conference Call Participants Ram Selvaraju - H.C. Wainwright Mark Connelly - Stephens Mitra Ramgopal - Sidoti & Company Lawrence Goldstein - Santa Monica Partners Operator Greetings. Welcome to the Balchem Corporation Financial Results Conference Call. At this time, all participants are in a lis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________________________ Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $.06-2/3 per share BCPC Nasdaq Global Market FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PUR ...

Financial Data and Key Metrics Changes - Balchem reported record quarterly consolidated net sales of $174.4 million, an increase of 11.1% compared to the prior year [11][12] - Net income for the first quarter was $19.8 million, up 5.2% from the prior year, translating to diluted net earnings per share of $0.61, an increase of $0.03 from the previous year [15] - Adjusted net earnings were $26.4 million or $0.81 per diluted share, up 11.4% compared to $23.7 million or $0.73 per diluted share in the prior year [15] - Consolidated gross margin dollars increased to $55.3 million, up 12.7% from $49.1 million in the prior year [13] - The company maintained a low net debt position of 1.1x trailing 12 months adjusted EBITDA, with cash on hand of $74 million [14][15] Business Line Data and Key Metrics Changes - Human Nutrition & Health segment achieved record sales of $95.5 million, a 12.2% increase from the prior year, driven by higher sales in food and beverage markets [16] - Animal Nutrition & Health segment also reported record sales of $48.6 million, a 12.2% increase, primarily due to higher volumes in ruminant and monogastric markets [18] - Specialty Products segment delivered record sales of $28.0 million, a 52% increase, driven by higher sales of ethylene oxide for medical device sterilization [20] Market Data and Key Metrics Changes - The impact of COVID-19 on demand varied, with anticipated weaker demand in food services and medical device sterilization due to fewer elective surgeries [9][10] - There was a noted increase in demand for certain products, such as immunity-boosting minerals and nutrients, as consumers focused on health during the pandemic [35] - The company experienced competitive price pressure in Europe, particularly in the Animal Nutrition & Health segment [19] Company Strategy and Development Direction - Balchem's strategic focus remains on health and nutrition, leading to a realignment of reporting segments to Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [12] - The company is committed to maintaining operational continuity during the pandemic, with a focus on employee safety and supply chain management [5][6] - Future investments will continue in key growth initiatives while navigating the uncertain market environment [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's balance sheet and liquidity position, allowing for continued investment despite market uncertainties [8][24] - The company anticipates challenges in sales due to weaker demand in certain markets but expects some offsetting demand in grocery store food products and functional technologies [9][10] - Management highlighted the resilience of the business model and the extraordinary response of employees during the pandemic [23] Other Important Information - The company has implemented cost-saving measures, including reducing capital expenditures and noncritical cash expenses to preserve cash [8] - Incremental costs related to COVID-19 response were approximately $1 million to $1.2 million in Q1, with similar expectations for Q2 [46] - The ERP implementation has been delayed by 6 to 9 months due to the pandemic, but remains on budget [48] Q&A Session Summary Question: How differential is the COVID-19 impact in the U.S. versus international markets, particularly Europe? - Management noted that Europe experienced an earlier impact and significant prebuying activity, which was not as pronounced in the U.S. [27] Question: Can you provide granularity on the locations of your plants relative to states' responses to the pandemic? - All manufacturing sites have operated at near-normal conditions, and state openings will facilitate shipments but not drastically change plant performance [29] Question: Do you expect ethylene oxide demand to rise due to the pandemic? - Demand has been balanced with both positive and negative impacts, with a slight decline in elective surgeries affecting the sterilization market [33] Question: Will there be any goodwill impairment charges due to COVID-19? - Management does not expect any goodwill impairment, citing sufficient cushion in their financials [39] Question: What are the potential impacts on the Animal Nutrition & Health division due to livestock culling? - There is uncertainty regarding the impact on demand due to processing site shutdowns and backlog, but the company has not yet seen significant effects [36] Question: How is the ERP implementation being impacted by COVID-19? - The implementation has been paused at additional sites, delaying completion by 6 to 9 months, but remains on budget [48] Question: Any changes to the dividend or potential acquisition activity? - The company is preserving cash and evaluating acquisition targets, but the process has slowed due to the pandemic [50][54]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________________________ Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $.06-2/3 per share BCPC Nasdaq Global Market FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PU ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 1-13648 ____________________________________________________________________________________________________________ ...

Balchem Corporation (NASDAQ:BCPC) Q4 2019 Earnings Conference Call February 21, 2020 11:00 AM ET Company Participants Martin Bengtsson - Chief Financial Officer Ted Harris - Chairman & Chief Executive Officer and President Conference Call Participants Brett Hundley - Seaport Global Ram Selvaraju - H.C. Wainwright Mitra Ramgopal - Sidoti Tony Polak - Aegis Capital Operator Greetings. Welcome to the Balchem Corporation Quarterly Conference Call for the Fourth Quarter 2019 Financial Results. At this time, all ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________________________ FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 1-13648 ...